HBV

Hepatitis B Virus (HBV) Infection Epidemiology and Market Forecast 2022-2032 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 15, 2022 - 12:06pm

This "Hepatitis B Virus (HBV) Infection- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hepatitis B Virus (HBV) Infection, historical and forecasted epidemiology as well as the Hepatitis B Virus (HBV) Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Points: 
  • This "Hepatitis B Virus (HBV) Infection- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hepatitis B Virus (HBV) Infection, historical and forecasted epidemiology as well as the Hepatitis B Virus (HBV) Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Hepatitis B Virus (HBV) Infection market report provides current treatment practices, emerging drugs, Hepatitis B Virus (HBV) Infection market share of the individual therapies, current and forecasted Hepatitis B Virus (HBV) Infection market Size from 2019 to 2032 segmented by seven major markets.
  • Drug chapter segment of the Hepatitis B Virus (HBV) Infection report encloses the detailed analysis of Hepatitis B Virus (HBV) Infection marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
  • The report covers the descriptive overview of Hepatitis B Virus (HBV) Infection, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
    Additionally, an all-inclusive account of both the current and emerging therapies for Hepatitis B Virus (HBV) Infection are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
    A detailed review of Hepatitis B Virus (HBV) Infection market; historical and forecasted is included in the report, covering drug outreach in the 7MM
    The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hepatitis B Virus (HBV) Infection market
    In the coming years, Hepatitis B Virus (HBV) Infection market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
    The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis B Virus (HBV) Infection R&D.

DGAP-News: Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A Solution

Retrieved on: 
Wednesday, August 10, 2022 - 1:11pm

However, most of the monkeypox virus particles exit due to cell lysis, and are infectious even though not fully mature; this mode is not affected by TPOXX.

Key Points: 
  • However, most of the monkeypox virus particles exit due to cell lysis, and are infectious even though not fully mature; this mode is not affected by TPOXX.
  • It had shown effectiveness in monkeys to increase survival upon monkeypox virus infection.
  • Thus there is a clear and immediate need for rapid new drug development against monkeypox virus and potential variants.
  • During the smallpox eradication program in the late 1960s, the vaccine used to prevent smallpox also helped curb monkeypox infections.

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Tuesday, August 9, 2022 - 9:15pm

OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Companys recent corporate developments.

Key Points: 
  • OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Companys recent corporate developments.
  • Second Quarter 2022 Financial Highlights:
    Cash position: As of June 30, 2022, cash and cash equivalents were $192.3 million, compared to $214.1 million as of December 31, 2021.
  • Revenues: Revenues were $17.1 million in the second quarter of 2022 compared to $15.0 million in the first quarter of 2022.
  • Research and development expenses: Research and development expenses were $9.7 million in the second quarter of 2022 compared to $10.7 million in the first quarter of 2022.

Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Tuesday, August 9, 2022 - 9:05pm

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced financial results and recent highlights for the second quarter ended June 30, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced financial results and recent highlights for the second quarter ended June 30, 2022.
  • Initial data are anticipated in the second half of 2022.
  • Cash, cash equivalents and marketable securities were $128.6 million as of June 30, 2022, compared to $146.5 million as of March 31, 2022.
  • More information about Assembly Bios risks and uncertainties are more fully detailed under the heading Risk Factors in Assembly Bios filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer

Retrieved on: 
Monday, August 8, 2022 - 9:00pm

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022.
  • View the full release here: https://www.businesswire.com/news/home/20220808005491/en/
    Scott T. Rottinghaus, M.D., Senior Vice President and Chief Medical Officer, Enanta Pharmaceuticals (Photo: Business Wire)
    We are delighted to welcome Scott Rottinghaus to our senior management team.
  • Earlier in his Pfizer career, he worked as a clinician on early stage clinical trials for influenza vaccine development.
  • Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release.

VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 8, 2022 - 1:00pm

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced financial results for the second quarter ending June 30, 2022 and provided a corporate update.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced financial results for the second quarter ending June 30, 2022 and provided a corporate update.
  • Cost of Revenue: Cost of revenues was $2.5 million in the second quarter of 2022 as compared to $2.6 million in the second quarter of 2021.
  • R&D expenses were offset by $1.0 million in the second quarter of 2022 and $3.3 million in the second quarter of 2021 by government grants and funding arrangements.
  • Foreign exchange loss for the second quarter of 2022 was $21.9 million as compared to $0.2 million for the second quarter of 2021.

Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 8, 2022 - 1:00pm

NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces financial results for the second quarter ended June 30, 2022 and provides a corporate update.

Key Points: 
  • NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company), today announces financial results for the second quarter ended June 30, 2022 and provides a corporate update.
  • We made substantial progress throughout the second quarter, highlighted by the FDA clearance of our IND application for systemically administered Decoy20.
  • The study protocol allows for exploration of additional dosing regimens, including continuous weekly administration after initial safety has been established.
  • Decoy20 has the potential to treat a wide range of solid tumors including hepatocellular, colorectal and pancreatic carcinomas.

INVESTOR DEADLINE: Investors in Enochian Biosciences Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – ENOB

Retrieved on: 
Saturday, August 6, 2022 - 9:15am

The Enochian Biosciences class action lawsuit captioned Chow v. Enochian Biosciences Inc., No.

Key Points: 
  • The Enochian Biosciences class action lawsuit captioned Chow v. Enochian Biosciences Inc., No.
  • Enochian Biosciences and its top management have credited Serhat Gumrukcu (Gumrukcu), Enochian Biosciences co-founder, as the inventor of the technology and science behind Enochian Biosciences product pipeline.
  • A lead plaintiff acts on behalf of all other class members in directing the Enochian Biosciences class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the Enochian Biosciences class action lawsuit.

Global Mice Model Market Analysis/Forecast Report 2022-2028: Rising Advancements in Gene Editing Tools & Rising Demand for Humanized Mice Models - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022 - 11:38am

The growing usage of mice models in virology and infectious diseases and the rising consumption of personalized medicine are bolstering the growth of the mice model market.

Key Points: 
  • The growing usage of mice models in virology and infectious diseases and the rising consumption of personalized medicine are bolstering the growth of the mice model market.
  • Moreover, the rising advancements in gene editing tools are likely to emerge as a significant future trend in the mice model market during the forecast period.
  • Based on type, the market is segmented into inbred mice, outbred mice, genetically engineered mice, hybrid mice, surgically modified mice, and spontaneous mutant mice.
  • Due to the aforementioned factors, the humanized mice models will continue to be widely used in the coming years, thereby contributing to the mice model market growth.

Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 4, 2022 - 12:30pm

WARMINSTER, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its second quarter 2022 financial results and provides corporate updates.

Key Points: 
  • WARMINSTER, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its second quarter 2022 financial results and provides corporate updates.
  • Finally, our financial position is strong with a projected cash runway into the second quarter of 2024.
  • The Company is on-track to report initial data in the second half of 2022.
  • The Company will provide an update with respect to the status and timing of this clinical trial in the second half of 2022.